News

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

The CATT Research Group April 2011 In 2005, clinical trials established the efficacy of ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use [Read More]

Maintaining Independence and Quality of Life

by Dan Roberts March 2011 The “English Longitudinal Study of Ageing” has found that people with poor eyesight are three to five times more likely than those with good eyesight to suffer from low quality of life, poor psychological health, and depression.1 When those inequalities are accounted for, however, the impact of poor eyesight itself [Read More]

“Crossing The Line From Visual To Nonvisual Skills”

An Interview with Maurice Peret (Blind Industries and Services of Maryland) Dan Roberts, Moderator International Low Vision Support Group February 10, 2011 Dan: Welcome to our webcast, Maurice. Please tell us how you became blind and how that led you into your work as rehabilitation trainer for Blind Industries and Services of Maryland. Maurice: How [Read More]

A Primer on the Use of Stem Cells in Ophthalmology

Irving J. Arons September 2, 2010 (Version 3, Updated September 14, 2010) I recently came across an interesting news release from International Stem Cell Corporation (ISCO) announcing that it had formed a new business unit, Cytovis, to focus on stem cell programs in ophthalmology, including CytoCor for the cornea and CytoRet for the retina. That [Read More]